Filing Flows › Pelthos Therapeutics (PTHS) › Stock forecast & fair value
Pelthos Therapeutics (PTHS) stock forecast and price target
Pelthos Therapeutics (PTHS) trades at $9.36. 7 analysts' median price target is $50.00 (+434%), from $30.00 to $64.00.
Pelthos Therapeutics' latest quarter
Pelthos Therapeutics, Q2 2026: revenue $15.6M, operating margin -111.0%, net loss $23.4M, operating cash flow −$7.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for PTHS stock?
The median of 7 analysts' 12-month targets is $50.00, +434% from $9.36; the range is $30.00 to $64.00. The average rating is strong buy.
Does Pelthos Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 25% of the quarters on record.
Is PTHS stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.